JP2018537093A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537093A5 JP2018537093A5 JP2018526182A JP2018526182A JP2018537093A5 JP 2018537093 A5 JP2018537093 A5 JP 2018537093A5 JP 2018526182 A JP2018526182 A JP 2018526182A JP 2018526182 A JP2018526182 A JP 2018526182A JP 2018537093 A5 JP2018537093 A5 JP 2018537093A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- amino acids
- domain
- group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021208914A JP2022046619A (ja) | 2015-11-20 | 2021-12-23 | 異所性石灰化障害を治療するための組成物およびそれを使用する方法 |
| JP2024014533A JP2024032952A (ja) | 2015-11-20 | 2024-02-02 | 異所性石灰化障害を治療するための組成物およびそれを使用する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257883P | 2015-11-20 | 2015-11-20 | |
| US62/257,883 | 2015-11-20 | ||
| PCT/US2016/063034 WO2017087936A1 (en) | 2015-11-20 | 2016-11-21 | Compositions for treating ectopic calcification disorders, and methods using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021208914A Division JP2022046619A (ja) | 2015-11-20 | 2021-12-23 | 異所性石灰化障害を治療するための組成物およびそれを使用する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018537093A JP2018537093A (ja) | 2018-12-20 |
| JP2018537093A5 true JP2018537093A5 (https=) | 2020-01-09 |
Family
ID=58719303
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018526182A Pending JP2018537093A (ja) | 2015-11-20 | 2016-11-21 | 異所性石灰化障害を治療するための組成物およびそれを使用する方法 |
| JP2021208914A Pending JP2022046619A (ja) | 2015-11-20 | 2021-12-23 | 異所性石灰化障害を治療するための組成物およびそれを使用する方法 |
| JP2024014533A Pending JP2024032952A (ja) | 2015-11-20 | 2024-02-02 | 異所性石灰化障害を治療するための組成物およびそれを使用する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021208914A Pending JP2022046619A (ja) | 2015-11-20 | 2021-12-23 | 異所性石灰化障害を治療するための組成物およびそれを使用する方法 |
| JP2024014533A Pending JP2024032952A (ja) | 2015-11-20 | 2024-02-02 | 異所性石灰化障害を治療するための組成物およびそれを使用する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20180371434A1 (https=) |
| EP (2) | EP4079322A1 (https=) |
| JP (3) | JP2018537093A (https=) |
| AU (2) | AU2016355715A1 (https=) |
| CA (1) | CA3005142A1 (https=) |
| WO (1) | WO2017087936A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3234116B1 (en) | 2014-12-19 | 2021-09-08 | Alexion Pharmaceuticals, Inc. | Methods of treating tissue calcification |
| WO2017087936A1 (en) | 2015-11-20 | 2017-05-26 | Yale University | Compositions for treating ectopic calcification disorders, and methods using same |
| US11364284B2 (en) | 2016-06-16 | 2022-06-21 | Inozyme Pharma, Inc. | Methods of treating myointimal proliferation |
| BR112019002355A2 (pt) | 2016-08-05 | 2019-07-16 | Yale University | composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme |
| EP3687565A1 (en) * | 2017-09-27 | 2020-08-05 | Alexion Pharmaceuticals, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) |
| EP3844280A4 (en) | 2018-08-31 | 2022-09-14 | Yale University | ENPP1 POLYPEPTIDES AND METHODS OF USE |
| MX2023000247A (es) * | 2020-07-02 | 2023-06-16 | Inozyme Pharma Inc | Composiciones y métodos para tratar la vasculopatía del aloinjerto, la enfermedad de moyamoya, el síndrome de moyamoya y la proliferación de la íntima. |
| WO2022076848A1 (en) * | 2020-10-08 | 2022-04-14 | Inozyme Pharma, Inc. | Liver specific production of enpp1 or enpp3 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4160452A (en) | 1977-04-07 | 1979-07-10 | Alza Corporation | Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| US5169645A (en) | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
| ATE173159T1 (de) | 1992-03-25 | 1998-11-15 | Depomed Systems Inc | Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
| AU1518595A (en) | 1994-01-14 | 1995-08-01 | Genentech Inc. | Antagonists to insulin receptor tyrosine kinase inhibitor |
| WO1997047285A1 (en) | 1996-06-10 | 1997-12-18 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| CA2290624C (en) | 1997-06-06 | 2006-12-05 | John W. Shell | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6043056A (en) | 1998-11-06 | 2000-03-28 | Incyte Pharmaceuticals, Inc. | Cell surface glycoproteins |
| CA2389236A1 (en) | 1999-11-02 | 2001-05-10 | Depomed, Inc. | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| ES2270982T3 (es) | 2000-02-04 | 2007-04-16 | Depomed, Inc. | Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero. |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| US7888372B2 (en) | 2001-03-23 | 2011-02-15 | National Institutes Of Health (Nih) | Compositions and methods for modulating bone mineral deposition |
| US20030191073A1 (en) * | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
| JP2004532259A (ja) | 2001-05-29 | 2004-10-21 | デポメッド ディベロップメント リミティド | 胃食道逆流症及び夜間に胃酸分泌が回復する現象の治療方法 |
| WO2003016475A2 (en) | 2001-08-14 | 2003-02-27 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| AU2003213246A1 (en) | 2002-02-21 | 2003-09-09 | University Of Virginia Patent Foundation | Bone targeting peptides |
| JP5199077B2 (ja) | 2005-06-10 | 2013-05-15 | アルタス ファーマシューティカルズ インコーポレイテッド | シュウ酸オキシダーゼ結晶の投与による、シュウ酸塩濃度を低下させるための方法 |
| PT2046373E (pt) | 2006-08-02 | 2013-05-06 | Althea Technologies Inc | Oxalato descarboxilase cristalizada e métodos de utilização |
| US20080273206A1 (en) * | 2007-04-23 | 2008-11-06 | University Of South Carolina | Biomimetic Mineralization Method and System |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| GB0803352D0 (en) | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
| ES2628841T3 (es) | 2010-03-12 | 2017-08-04 | Alexion Pharmaceuticals, Inc. | Proteínas de fusión npp1 |
| KR101772366B1 (ko) | 2011-03-11 | 2017-08-28 | 알렉시온 파마슈티칼스, 인코포레이티드 | Ｎｐｐ１ 융합 단백질 |
| WO2014126965A2 (en) | 2013-02-13 | 2014-08-21 | Yale University | Compositions and methods for treating pathological calcification and ossification |
| CN105378075B (zh) | 2013-03-15 | 2022-04-05 | Atyr 医药公司 | 组氨酰-trna合成酶-fc缀合物 |
| EP3234116B1 (en) | 2014-12-19 | 2021-09-08 | Alexion Pharmaceuticals, Inc. | Methods of treating tissue calcification |
| KR20250078598A (ko) | 2015-05-19 | 2025-06-02 | 예일 유니버시티 | 병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법 |
| WO2017087936A1 (en) | 2015-11-20 | 2017-05-26 | Yale University | Compositions for treating ectopic calcification disorders, and methods using same |
-
2016
- 2016-11-21 WO PCT/US2016/063034 patent/WO2017087936A1/en not_active Ceased
- 2016-11-21 CA CA3005142A patent/CA3005142A1/en active Pending
- 2016-11-21 EP EP22160246.9A patent/EP4079322A1/en active Pending
- 2016-11-21 EP EP16867323.4A patent/EP3377105A4/en not_active Withdrawn
- 2016-11-21 US US15/777,446 patent/US20180371434A1/en not_active Abandoned
- 2016-11-21 AU AU2016355715A patent/AU2016355715A1/en not_active Abandoned
- 2016-11-21 JP JP2018526182A patent/JP2018537093A/ja active Pending
-
2020
- 2020-10-20 US US17/075,398 patent/US20210032610A1/en not_active Abandoned
-
2021
- 2021-12-23 JP JP2021208914A patent/JP2022046619A/ja active Pending
-
2022
- 2022-12-19 US US18/068,256 patent/US12234489B2/en active Active
-
2023
- 2023-09-07 AU AU2023226739A patent/AU2023226739A1/en active Pending
-
2024
- 2024-02-02 JP JP2024014533A patent/JP2024032952A/ja active Pending
-
2025
- 2025-01-22 US US19/033,863 patent/US20250388882A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537093A5 (https=) | ||
| JP2024010052A (ja) | 組織石灰化の治療方法 | |
| JP6722175B2 (ja) | 代謝障害を処置するための組成物及びその使用方法 | |
| JP5653909B2 (ja) | 抗Ｓｉｇｌｅｃ−１５抗体 | |
| JP6059205B2 (ja) | ＣＤＲ改変抗Ｓｉｇｌｅｃ−１５抗体 | |
| CA2931309C (en) | Compositions and methods for treating pulmonary hypertension | |
| US10646544B2 (en) | Pharmaceutical composition for treating bone diseases which comprises protein comprising Frizzled 1, Frizzled 2 or Frizzled 7 extracellular cysteine-rich domain | |
| JP2018516566A5 (https=) | ||
| JP2013127002A5 (https=) | ||
| JP2010518079A5 (https=) | ||
| CN112741804A (zh) | 含有抗pd-l1抗体的稳定制剂 | |
| SI2802606T1 (en) | Improves the transfer of healing molecules through the hematoencephalic barrier | |
| JP2024532831A (ja) | アクチビン受容体ｉｉ型シグナル伝達阻害剤を使用する方法 | |
| CN120623353A (zh) | 多特异性wnt替代分子和其用途 | |
| JP2011520793A5 (https=) | ||
| TW201920242A (zh) | Glp-2融合多肽及用於治療及預防胃腸病症之用途 | |
| JPWO2013147212A1 (ja) | 新規抗Ｓｉｇｌｅｃ−１５抗体 | |
| JP2008521426A5 (https=) | ||
| RU2007119989A (ru) | Композиции, слитые конструкции и конъюгаты plad домена | |
| JP2025116068A (ja) | 腎臓活性融合タンパク質及びそれを使用する治療方法 | |
| JP2026504047A (ja) | 脂質結合タンパク質分子療法 | |
| JP2021535078A (ja) | 骨の疾患の治療に用いるためのトランスフェリン受容体２のアンタゴニスト及びアゴニスト | |
| US20250352618A1 (en) | Methods of treating bronchopulmonary dysplasia | |
| EP4582457A1 (en) | Artificial protein and pharmaceutical composition | |
| WO2025174995A1 (en) | Methods of using activin a and myostatin signaling inhibitors |